This assay is intended for the in vitro quantitative measurement of hepatitis C virus（HCV）RNA in human plasma.This assay is suitable for patients who need to be diagnosed for HCV infection and for HCV undergoing antiviral treatment. The test results should not be used as the soleindicator for evaluating the patient's condition and must be combined with the patient'sclinical manifestations and other laboratory tests for a comprehensive analysis of thecondition. This assay is not intended for donor screening.
World's first ready‑to‑use lyophilized reagent for viral load testing
No additional reagent consumption required, with traceability to International Standards
UNG/dUTP carryover prevention + Mineral oil seal
Targets HCV’s conserved 5'UTR region to reliably detect all genotypes 1‑6.
| Method | RT‑PCR (Fluorescent Probe) |
| Target | HCV RNA (5'UTR conserved region) |
| Linear Range | 20 IU/mL – 1.0×10⁸ IU/mL |
| Limit of Detection (LoD) | 20 IU/mL |
| Limit of Quantitation (LoQ) | 20 IU/mL |
| Detectable Genotypes | Genotypes 1, 2, 3, 4, 5, 6 |
| Sample Type | Plasma (EDTA anticoagulant) |
| Sample Volume | 200 μL |
| Precision (CV) | ≤5% (logarithmic values) |
| Storage Conditions | 2‑8°C |
| Shelf Life | 24 months |
Cat. No. | Product Name | Spec. | Certificate |
M1031 | Molvizon HCV | 48 Tests/Kit | NMPA |
M1032 | 96 Tests/Kit | NMPA | |
M1033 | 192 Tests/Kit | NMPA |
丽珠试剂官方
丽珠试剂资讯
粤公网安备 44049002000690号
Technical Support:E-net